19 June 14:48

News
Foto Gilead Pharma
Yeztugo, a drug developed by Gilead, has been authorized in the United States as a preventive treatment against HIV. It requires only two injections a year, unlike current treatments that require daily pills. While the treatment could revolutionize the fight against the AIDS epidemic, cost remains a crucial issue, with an estimated annual price tag of about $25,000. UNAIDS director Winnie Byanyima emphasized the importance of making the drug affordable to have a real impact in the fight against AIDS.
Sources

Tratament promiţător împotriva HIV-SIDA. Producătorii promit prețuri accesibil

Statele Unite autorizează un nou tratament preventiv, foarte promiţător, împotriva HIV, virusul care cauzează SIDA

FDA approves first twice-yearly injection that prevents HIV infection

US approves promising preventive HIV treatment

Groundbreaking twice-a-year HIV drug that could stop transmission approved